Sunday, January 16 2022

Article 8.01 Other events.

On November 26, 2021, Biohaven Pharmaceutical Holding Company Ltd. (the
"Company") filed a prospectus supplement to its Registration Statement on Form
S-3 filed with the U.S. Securities and Exchange Commission (the "Commission")
(No. 333-253946) (the "Registration Statement"), under the Securities Act of
1933, as amended, with respect to the resale by the selling shareholder named
therein of 29,297 common shares, no par value, of the Company that were issued
by the Company to such selling shareholder as share consideration in connection
with the transactions and business arrangements described therein.

In connection with filing of such prospectus supplement, the Company is filing a
legal opinion as Exhibit No. 5.1 to this Current Report on Form 8-K, which is
incorporated by reference into the Registration Statement.


Item 9.01 Financial statements and supporting documents.

(d) Exhibits
      Exhibit Number                                      Exhibit Description
           5.1                     Opinion of Maples & Calder.
           23.1                    Consent of Maples & Calder (included in Exhibit 5.1).
           104                   The cover page of this Current Report on Form 8-K formatted as Inline
                                 XBRL.



                                       1

————————————————– ——————————

© Edgar online, source Previews


Source link

Previous

Join DJ Sbu and Crypto University for an interactive workshop

Next

Stephen Sondheim: master craftsman who reinvented musical matrices at 91 | Stephen Sondheim

Check Also